Results 201 to 210 of about 1,745,075 (289)
Impact of the COVID-19 pandemic on the utilization of healthcare
Chung-liang Shih +2 more
doaj +1 more source
Patient satisfaction among national health insurance enrollees in an accredited hospital of Kathmandu Valley: A cross-sectional, mixed methods study. [PDF]
Shrestha S +3 more
europepmc +1 more source
Objective Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint pain, swelling, and stiffness. Although smoking is a well‐established risk factor for RA, the role of occupational inhalants in RA development is less well recognized.
Qianwen Liu +7 more
wiley +1 more source
Disparities in survival after hip fractures in Chile in patients above 60 years: the impact of the operating room management. [PDF]
Barahona M, Matus O, Mondschein S.
europepmc +1 more source
Objective We evaluated serious infection risk in offspring exposed to tumor necrosis factor inhibitors (TNFi) in utero, separated by TNFi timing and placental transfer ability. Methods Using MarketScan (2011–2021), we identified offspring born to mothers with chronic inflammatory diseases.
Leah K. Flatman +6 more
wiley +1 more source
Healthcare Access and Health Status by Primary Source of Health Insurance and Occupation. [PDF]
Silver SR, Li J, Asfaw A.
europepmc +1 more source
Objective Using a hydroxychloroquine (HCQ) dose of 5 mg/kg/day in systemic lupus erythematosus (SLE) is associated with a higher risk of flares; HCQ blood level monitoring could be a better way to adjust the HCQ dose. We studied the upper threshold for a reference range of HCQ levels to inform routine monitoring.
Shivani Garg +42 more
wiley +1 more source
Sociodemographic Determinants of Telemedicine Uptake Among Adults in the United States. [PDF]
Mensah EA +8 more
europepmc +1 more source
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate to severe systemic lupus erythematosus (SLE) activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly
Susan Manzi +12 more
wiley +1 more source

